Leeward Investments LLC MA Cuts Stake in Encompass Health Corporation $EHC

Leeward Investments LLC MA lowered its holdings in Encompass Health Corporation (NYSE:EHC) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 341,734 shares of the company’s stock after selling 9,387 shares during the quarter. Encompass Health comprises approximately 2.2% of Leeward Investments LLC MA’s investment portfolio, making the stock its 2nd largest holding. Leeward Investments LLC MA owned about 0.34% of Encompass Health worth $43,407,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Norges Bank bought a new stake in Encompass Health in the second quarter worth about $139,536,000. 8 Knots Management LLC bought a new position in shares of Encompass Health in the second quarter worth $78,644,000. Thrivent Financial for Lutherans boosted its position in shares of Encompass Health by 57.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after acquiring an additional 437,464 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Encompass Health during the 2nd quarter valued at $34,719,000. Finally, Raymond James Financial Inc. lifted its stake in Encompass Health by 31.5% during the second quarter. Raymond James Financial Inc. now owns 1,143,642 shares of the company’s stock worth $140,245,000 after purchasing an additional 274,142 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $110.02 on Friday. The business has a fifty day moving average price of $103.93 and a 200-day moving average price of $114.54. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.08 and a quick ratio of 1.14. The company has a market capitalization of $11.07 billion, a PE ratio of 19.86, a PEG ratio of 2.10 and a beta of 0.73. Encompass Health Corporation has a 1-year low of $92.53 and a 1-year high of $127.99.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.29 by $0.17. The company had revenue of $3.09 billion for the quarter, compared to the consensus estimate of $1.54 billion. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. Encompass Health’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.17 EPS. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, equities analysts expect that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Insider Transactions at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 150,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the sale, the chief executive officer directly owned 377,070 shares in the company, valued at approximately $42,096,094.80. This trade represents a 28.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on EHC. Zacks Research downgraded shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. Barclays upped their target price on Encompass Health from $150.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, Raymond James Financial raised Encompass Health to a “strong-buy” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Encompass Health currently has a consensus rating of “Buy” and an average price target of $143.29.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.